Search

Your search keyword '"Chalmers J.D."' showing total 134 results

Search Constraints

Start Over You searched for: Author "Chalmers J.D." Remove constraint Author: "Chalmers J.D."
134 results on '"Chalmers J.D."'

Search Results

1. Long term health outcomes in people with diabetes 12 months after hospitalisation with COVID-19 in the UK: a prospective cohort study

3. ECFS standards of care on CFTR-related disorders: Identification and care of the disorders

5. Determinants of recovery from post-COVID-19 dyspnoea: analysis of UK prospective cohorts of hospitalised COVID-19 patients and community-based controls

6. Prevalence of physical frailty, including risk factors, up to 1 year after hospitalisation for COVID-19 in the UK: a multicentre, longitudinal cohort study

7. SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination

8. Diagnostic delay and access to care in bronchiectasis: data from the EMBARC/ELF patient survey

10. Changes in Blood Immune Cell Transcriptomes Associate With Disease Severity, Infection, and Inflammation in Bronchiectasis Patients: Data From the EMBARC-BRIDGE Study

11. Net and Cell Count Differentials Among NTM +/- Bronchiectasis Patients With Cavitary and Non-cavitary Disease

14. Clinical Efficacy of Anti-glycopeptidolipid-core IgA Test for Screening Nontuberculous Mycobacterial Infection in Bronchiectasis: A Multicenter European Study

15. Microbiologic Outcomes From a Randomized, Double-blind Trial of Amikacin Liposome Inhalation Suspension in Adults With Newly Diagnosed or Recurrent Mycobacterium Avium Complex Lung Disease: The ARISE Study

17. Sputum Dipeptidyl Peptidase-1 Activity Associates With Inflammation and Disease Severity in Bronchiectasis: Data From the EMBARC-BRIDGE Study

25. A Bispecific Monoclonal Antibody Targeting Psl and PcrV Enhances Bronchiectasis Patient Neutrophil-Mediated Killing of Pseudomonas Aeruginosa

28. The Effect of Inhaled Corticosteroid Withdrawal on the Airway Metagenome and Antimicrobial Resistance: Data From the INCOGNITO Trial

29. Inflammatory Molecular Endotypes of Bronchiectasis Are Related to Microbiome Structure and Diversity: A European Multicenter Cohort Study

30. Prevalence of physical frailty, including risk factors, up to 1 year after hospitalisation for COVID-19 in the UK: a multicentre, longitudinal cohort study

31. SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination

34. ePS3.08 Inhaled powder tobramycin (TIP): cyclical versus continuous treatment: iBEST Study

35. Study Design of a Phase II, Randomized, Double-Blind, Placebo-Controlled Trial of a Novel Cathepsin C Inhibitor BI 1291583 in Patients with Bronchiectasis

37. The Relationship Between Airway Interleukin-1 Beta, Microbial Dysbiosis and Mucus Hyperconcentration in Bronchiectasis: The EMBARC-BRIDGE Study

39. Characterization of Ciliary Function in Bronchiectasis (EMBARC-BRIDGE Study)

40. A Randomized Double-Blind Placebo-Controlled Trial of Dipeptidyl Peptidase-1 Inhibition in Hospitalized Patients with COVID-19: The STOP-COVID19 Trial

41. Transcriptomic Changes in Hospitalised COVID19 Patients Across 29 Days Provide Insight into the Systemic Immune Response and Disease Outcomes: Results from PREDICT-COVID19

43. The Effect of Inhaled Corticosteroid Withdrawal on Inflammation and the Airway Microbiome in COPD: The INCOGNITO Trial

44. Topological Data Analysis (TDA) of Allergic Sensitization in Bronchiectasis and COPD

48. The Seroprevalence and Protective Effect of SARS-COV-2 Antibodies in Scottish Healthcare Workers

49. The Metagenomic ‘Bacteriophagome’ in Bronchiectasis

50. Concurrent Randomized, Double-Blind, Placebo-Controlled Trials to Validate Patient-Reported Outcome (PRO) Instruments and Assess Clinical Benefit of Treatment in Adults with Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium AviumComplex (MAC)

Catalog

Books, media, physical & digital resources